It has been shown that in adults with OI, synthetic parathyroid hormone (teriparatide), which is also used in postmenopausal osteoporosis treatment, leads to an increase in bone mass density [30,31,32]. The gene discussed is PTH; the disease is osteogenesis imperfecta.